TITLE

Randomized Study of Two "Rescue" Therapies for Helicobacter pylori-Infected Patients After Failure of Standard Triple Therapies

AUTHOR(S)
Perri, Francesco; Festa, Virginia; Clemente, Rocco; Villani, Maria Rosaria; Quitadamo, Michele; Caruso, Nazario; Bergoli, Michelle Li; Andriulli, Angelo
PUB. DATE
January 2001
SOURCE
American Journal of Gastroenterology;Jan2001, Vol. 96 Issue 1, p58
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVES: A novel rifabutin-based therapy is able to cure Helicobacter pylori infection in most patients who have failed eradication after standard proton pump inhibitor (PPI)-based triple therapy. We compared this regimen with the quadruple therapy. METHODS: A total of 135 patients were randomized into three groups who were treated for 10 days with pantoprazole 40 mg b.i.d., amoxycillin 1 g b.i.d., and rifabutin 150 mg o.d. (RAP150 group), or 300 mg o.d. (RAP300 group), and pantoprazole 40 mg b.i.d., metronidazole 250 mg t.i.d., bismuth citrate 240 mg b.i.d., and tetracycline 500 mg q.i.d. (QT group). Before therapy, patients underwent endoscopy with biopsies for histology, culture and antibiotic susceptibility tests. H. pylori eradication was assessed by the 13C-urea breath test. RESULTS: On intention-to-treat analysis, eradication rates (with 95% confidence intervals [CI]) were 66.6% (53-80%) in the RAP150 and QT groups, respectively, and 86.6% (76-96%) in RAP300 group (p < 0.025). Most patients harboring metronidazole- and clarithromycin-resistant strains were eradicated at an equal rate by each of the three regimens. Side effects were observed in 9% and 11% of rifabutin-treated patients, and in 47% of those on quadruple therapy (p < 0.0001). CONCLUSIONS: In patients who failed standard eradicating treatments, a 10-day course of rifabutin with pantoprazole and amoxycillin is more effective and well tolerated than the quadruple therapy.
ACCESSION #
17634767

 

Related Articles

  • Recent Advances in the Treatment of Helicobacter pylori Infection. Bergamaschi, Antonio; Magrini, Andrea; Pietroiusti, Antonio // Recent Patents on Anti-Infective Drug Discovery;Nov2007, Vol. 2 Issue 3, p197 

    The approach to the treatment of Helicobacter pylori infection has changed during the last years. In fact, during the last decade, the success rate of usual eradication regimens, based on a proton pump inhibitor plus clarithromycin associated with amoxicillin or metronidazole, declined from over...

  • Rabeprazole. Prakash, A.; Faulds, D. // Drugs;Feb1998, Vol. 55 Issue 2, p261 

    â–´ Rabeprazole is a proton pump inhibitor with antisecretory properties. In vitro animal experiments have indicated that the inhibition of the proton pump by rabeprazole is partially reversible. â–´ Rabeprazole has 2- to 10-fold greater antisecretory activity than omeprazole in vitro....

  • Molecular mechanisms of Helicobacter pylori resistance to metronidazole. Pietroiusti, A.; Fontana, C.; Favaro, M.; Minelli, S.; Favalli, C.; Magrini, A.; Bergamaschi, A.; Iannaccone, U.; Galante, A. // Gut;Sep2002 Supplement 2, Vol. 51, pA4 

    Triple-drug regimens (metronidazole in combination with either amoxicillin or clarithromicin and a proton pump inhibitor) are highly effective in treating Helicobacter pylori infection, but bacterial resistance to metronidazole and clarithromycin, is a serious and increasing problem. It has been...

  • Meta-analysis: Duration of First-Line Proton-Pump Inhibitor--Based Triple Therapy for Helicobacter pylori Eradication. Fuccio, Lorenzo; Minardi, Maria Eugenia; Zagari, Rocco Maurizio; Grilli, Diego; Magrini, Nicola; Bazzoli, Franco // Annals of Internal Medicine;10/16/2007, Vol. 147 Issue 8, p553 

    Background: Proton-pump inhibitor (PPI)—based triple therapy is the recommended first-line treatment for Helicobacter pylori infection. A consensus on treatment duration is lacking. Purpose: To summarize the benefits and harms of different durations of PPI-based triple therapy. Data...

  • Third-Line Rescue Therapy with Levofloxacin After Two H. pylori Treatment Failures. Gisbert, Javier P.; Castro-Fernández, Manuel; Bermejo, Fernando; Pérez-Aisa, Angeles; Ducons, Julio; Fernández-Bermejo, Miguel; Bory, Felipe; Cosme, Angel; Benito, Luis-Miguel; López-Rivas, Laureano; Lamas, Eloisa; Pabón, Manuel; Olivares, David // American Journal of Gastroenterology;Feb2006, Vol. 101 Issue 2, p243 

    AIM: Eradication therapy with proton pump inhibitor, clarithromycin and amoxicillin fails in a considerable number of cases. A rescue therapy still fails in more than 20% of the cases. Our aim was to evaluate the efficacy and tolerability of a third-line levofloxacin-based regimen in patients...

  • Study supports NICE on dyspepsia. Baines, Emma // GP: General Practitioner;5/24/2004, p19 

    Treatment with a proton pump inhibitor (PPI) followed by test-and-treat for Helicobacter pylori is the best strategy for managing patients with dyspepsia, according to Dutch research. The findings support recommendations made by NICE in its draft guidance on the management of chronic dyspepsia,...

  • PPIs, H. pylori, and Atrophic Gastritis: Putting the Issue to Rest? DiBaise, John K.; Thompson, Jon S. // American Journal of Gastroenterology;Dec1999, Vol. 94 Issue 12, p3403 

    Discusses research being done on the effect of acid suppression therapy on the development of atrophic gastritis in individuals infected with Helicobacter pylori. Reference to a study by L. Lundell, P. Miettinen, H. E. Myrvold et al., published in the 1999 issue of the "American Journal of...

  • Eradication therapies for Helicobacter pylori. Borody, Thomas J.; Shortis, Nicholas P.; Reyes, Eppie // Journal of Gastroenterology;1998 Supplement 10, Vol. 33, p53 

    Eradication therapies for Helicobacter pylori evolved from monotherapy, through dual therapies and finally to bismuth-based triple therapies by the mid-1980s. The advent of proton pump inhibitors (PPI) and clarithromycin added a new impetus in the development of newer and often more effective...

  • Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection. Dore, M.P.; Graham, D.Y.; Mele, R.; Marras, L.; Nieddu, S.; Manca, A.; Realdi, G. // American Journal of Gastroenterology;Apr2002, Vol. 97 Issue 4, p857 

    OBJECTIVE:Helicobacter pylori (H. pylori) eradication rates in northern Sardinia using standard 1-wk triple therapies (i.e., a proton pump inhibitor and two antibiotics) are typically <60%, primarily because of antibiotic resistance. The aim of this study was to test b.i.d. quadruple therapy as...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics